BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23443316)

  • 1. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.
    Le Gendre O; Sookdeo A; Duliepre SA; Utter M; Frias M; Foster DA
    Mol Cancer Res; 2013 May; 11(5):474-81. PubMed ID: 23443316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle.
    Saqcena M; Patel D; Menon D; Mukhopadhyay S; Foster DA
    Cell Cycle; 2015; 14(14):2285-92. PubMed ID: 25945415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest.
    Yellen P; Chatterjee A; Preda A; Foster DA
    Cancer Lett; 2013 Jun; 333(2):239-43. PubMed ID: 23376634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Par-4 mediated Smad4 induction in PDAC cells restores canonical TGF-β/ Smad4 axis driving the cells towards lethal EMT.
    Mohd Faheem M; Rasool RU; Ahmad SM; Jamwal VL; Chakraborty S; Katoch A; Gandhi SG; Bhagat M; Goswami A
    Eur J Cell Biol; 2020 May; 99(4):151076. PubMed ID: 32439219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
    PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
    Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
    Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.
    Gadir N; Jackson DN; Lee E; Foster DA
    Oncogene; 2008 Feb; 27(8):1055-62. PubMed ID: 17700525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.
    Zhou J; Wu J; Zheng F; Jin M; Li H
    J Diabetes; 2015 Mar; 7(2):231-9. PubMed ID: 24909811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
    Li B; Yang J; Lu Z; Liu B; Liu F
    J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
    J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
    Gupta M; Ansell SM; Novak AJ; Kumar S; Kaufmann SH; Witzig TE
    Blood; 2009 Oct; 114(14):2926-35. PubMed ID: 19641186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.
    Fullerton PT; Creighton CJ; Matzuk MM
    Mol Endocrinol; 2015 Oct; 29(10):1440-53. PubMed ID: 26284758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas.
    Sebestyén A; Márk Á; Hajdu M; Nagy N; Molnár A; Végső G; Barna G; Kopper L
    Cytokine; 2015 Jun; 73(2):219-24. PubMed ID: 25794661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.